Polθ inhibitors elicit BRCA-gene synthetic lethality and target PARP inhibitor resistanceDiana Zatreanu, Christopher J. Lord, Martin E. Swarbrick et al.|Nature Communications|2021Cited by 358
Abstract P056: Polθ inhibitors elicit <i>BRCA</i>-gene synthetic lethality and target PARP inhibitor resistanceDiana Zatreanu, Christopher J. Lord, Helen M.R. Robinson et al.|Molecular Cancer Therapeutics|2021Cited by 3
Abstract LB520: A pharmacodynamic platform using liquid biopsy to support dose selection for the ATR inhibitor ART0380 (IACS-030380)Manish R. Patel, Melissa M. Johnson, Kathleen N. Moore et al.|Cancer Research|2022Cited by 3
Abstract 5697: Targeting PARP inhibitor resistance with Polθ inhibitorsDiana Zatreanu, Christopher J. Lord, Helen M. Robinson et al.|Cancer Research|2022Cited by 1
Abstract 3149: Micronuclei (MN) dynamics in preclinical models and in patient reticulocytes as a pharmacodynamic biomarker for the first in class DNA polymerase theta (PolΘ) inhibitor ART6043Colette L Baxter, Graeme C. Smith, Timothy A. Yap et al.|Cancer Research|2026Cited by 0